Reconciling primary care and specialist perspectives on prostate cancer screening.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 23149535.
- Also identified by DOI 10.1370/afm.1399 and PMC identifier 3495932.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
When specialists propose screening guidelines for primary care clinicians to implement, differences in perspectives between the 2 groups can create conflicts. Two recent specialty organization guidelines illustrate this issue. The American Urological Association guideline panel and National Comprehensive Cancer Network recommend that average-risk men first be counseled about the risks and benefits of prostate-specific antigen screening for prostate cancer at age 40 rather than at the previously recommended age of 50 years. There is no direct evidence, however, that this recommendation has any impact on prostate cancer-specific mortality. To avoid distracting primary care clinicians from providing services with proven benefit and value for patients, professional organizations should follow appropriate standards for developing guidelines. Primary care societies and health care systems should also be encouraged to evaluate the evidence and decide whether implementing the recommendations are feasible and appropriate.
Medical subject headings
- Early Detection of Cancer
- Primary Health Care
- Prostate-Specific Antigen
- Prostatic Neoplasms